Why the study?
What are the risks of non-cardiac surgery following recent coronary artery stenting, and how should perioperative antiplatelet therapy be managed?
What are the risks of non-cardiac surgery following recent coronary artery stenting, and how should perioperative antiplatelet therapy be managed?
Careless preoperative withdrawal of antiplatelet therapy must be avoided in patients with recent coronary stents undergoing non-cardiac surgery due to the high risk of stent thrombosis and mortality.
Answers are grounded in this paper and cite their sources.
High mortality risk after stenting in surgical patients warrants perioperative caution; leaves open optimal antiplatelet strategies pending prospective data.
SUMMARY Percutaneous coronary intervention with intracoronary stenting is a routine procedure in the treatment of coronary artery disease today. While complication rates of in‐stent stenosis and thromboembolic complications dropped over the years due to improved stent design, material, coating and consequent antiplatelet medication, major concerns remain relating to non‐cardiac surgery following briefly after coronary artery stent implantation. A mortality rate of almost 5% has to be expected in a mixed surgical and orthopedic population after coronary artery stenting. Data about cardiac surgery briefly after stent implantation are not available. The risk of major bleeding following continued perioperative antiplatelet therapy has to be balanced against the risk of stent thrombosis by discontinuation of antiplatelet medication in these patients. The careless withdrawal of antiplatelet therapy preoperatively must be avoided.
No takes yet. Share an insight, caveat, or question.
Busley et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: